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Abstract
Background: Myostatin is a negative regulator of skeletal muscle mass whose activity is upregulated in adult heart failure
(HF); however, its role in congenital heart disease (CHD) is unknown.
Methods: We studied myostatin and IGF-1 expression via Western blot in cardiac tissue at varying degrees of myocardial
dysfunction and after biventricular support in CHD by collecting myocardial biopsies from four patient cohorts: A) adult
subjects with no known cardiopulmonary disease (left ventricle, LV), (Adult Normal), (n=5); B) pediatric subjects undergoing
congenital cardiac surgery with normal RV size and function (right ventricular outflow tract, RVOT), (n=3); C) pediatric
subjects with worsening but hemodynamically stable LV failure [LV and right ventricle (LV, RV,)] with biopsy collected at the
time of orthotopic heart transplant (OHT), (n=7); and D) pediatric subjects with decompensated bi-ventricular failure on
BiVAD support with biopsy collected at OHT (LV, RV, BiVAD), (n=3).
Results: The duration of HF was longest in OHT patients compared to BIVAD. The duration of BiVAD support was 4.361.9
days. Myostatin expression was significantly increased in LV-OHT compared to RV-OHT and RVOT, and was increased more
than double in decompensated biventricular HF (BiVAD) compared to both OHT and RVOT. An increased myostatin/IGF-1
ratio was associated with ventricular dysfunction.
Conclusions: Myostatin expression in increased in CHD, and the myostatin/IGF-1 ratio increases as ventricular function
deteriorates. Future investigation is necessary to determine if restoration of the physiologic myostatin/IGF-1 ratio has
therapeutic potential in HF.
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Introduction
Myostatin, a member of the TGF-b family of proteins, has been
well-established as a negative regulator of skeletal muscle mass [1].
In addition, myostatin has been demonstrated to be upregulated in
myocardial tissue in both small and large animal models of heart
failure (HF) [2,3,4], where it has been proposed to play a role in
the regulation of cardiac remodeling. Indeed, inhibition of
myostatin in the mdx mouse, a model of Duchenne muscular
dystrophy (DMD), accelerates the development of dilated
cardiomyopathy [5]. Recently, we demonstrated that myostatin
activation is increased in adult patients with advanced HF and
after mechanical unloading and that myostatin latent complex is
increased in the serum of adult patients in HF [6]. Other
investigators have also reported that myostatin is increased in the
serum [7], heart [8], and skeletal muscle [9] of adult HF patients.
To date, the regulation of myostatin in congenital heart disease
(CHD) has not been described. Therefore, in this study, our goal
was to quantify myostatin expression in CHD in patients with both
compensated LV failure and with decompensated biventricular
failure on BiVAD support. In addition, we also sought to quantify
IGF-1 expression, as the relationship between myostatin and IGF-
1 in the heart is poorly understood [10,11].
Methods
Ethics Statement
This study met all institutional guidelines and New York State
organ donation guidelines regarding use of clinical data, ethical
treatment of patients adhering to Declaration of Helsinki
principles, and procurement of tissue for research. This study
was approved by the Institutional Review Board of Columbia
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IRB-AAAF9485), the New York State Organ Donor Network, and
met all institutional guidelines regarding handling of tissue
specimens, HIPAA security of clinical information. Tissue from
all subjects was collected at Columbia University Medical Center,
while tissue from rejected organ donors was collected at local
harvest sites, in accordance to New York Organ Donor Network
guidelines.
Consent for this study for pediatric study subjects (IRB-
AAAF0646) was waived by the Columbia University Medical
Center Institutional Review Board for the following reasons: 1) all
tissue collected was tissue that would otherwise have been
discarded, 2) the difficulty of pre-operatively predicting which
surgery would yield appropriate type and amount of specimen
tissue was too high to require consent for all congenital patients
undergoing surgery (our yield for tissue was ,10/400 surgeries),
and 3) the study posed no risk to subjects (to reiterate, all tissue
samples were tissue that would otherwise have been discarded),
and 4) all tissue and clinical data was de-identified. For adult
donor hearts (IRB-AAAD6369, IRB-AAAF9485), consent for
research was documented by the New York State Organ Donor
Network; the Columbia University Medical Center Institutional
Review Board waived consent for adult donor hearts, given that
consent for research was already documented by the New York
Organ Donor Network and that tissue would otherwise have been
discarded. No identifying information from these patients was
collected.
Study Design
Myocardial biopsies were prospectively collected from four
patient cohorts: A) adult subjects with no known cardiopulmonary
disease (left ventricle, LV), (Adult Normal), (n=5); B) pediatric
subjects undergoing congenital cardiac surgery with normal RV
size and function (right ventricular outflow tract, RVOT), (n=3);
C) pediatric subjects with worsening but hemodynamically stable
LV failure [LV and right ventricle (LV, RV,)], with biopsy
collected at time of orthotopic heart transplant (OHT), (n=7); and
D) pediatric subjects with decompensated bi-ventricular failure on
BiVAD support with biopsy collected at the time of OHT (LV,
RV, BiVAD), (n=3).
Study Subjects and Myocardial Tissue Collection
Normal Subjects. Subjects with no known cardiopulmonary
disease whose organs were listed but were unable to be placed at
the time of organ recovery for heart transplantation and who
consented to tissue for research purposes by the New York Organ
Donor Network were included in this study from 2004 to 2006.
Organs were unable to be placed primarily due to logistical and
timing constraints and matching incompatibilities - no organ was
rejected from transplantation due to depressed ventricular
function. At the time of organ recovery, cardioplegia with
Celsior solution was administered in the standard fashion. A
section (40 mg) of the left ventricle (LV) apex was immediately
obtained at the conclusion of cardioplegia perfusion and flash
frozen in liquid nitrogen for analysis.
Pediatric Patients. Children with complex CHD requiring
cardiac surgery, cardiomyopathy with LV failure requiring
orthotopic heart transplantation (OHT), or biventricular heart
failure necessitating BiVAD support prior to OHT were enrolled
in this study from 2007–2010 at the Children’s Hospital of New
York, Presbyterian Hospital - Columbia Campus. In patients
undergoing complex CHD surgery, a sample of right ventricular
outflow tract (RVOT) was obtained and flash frozen in liquid
nitrogen for analysis. The Thoratec CentriMag (Pleasanton, CA)
continuous flow pump was implanted in all patients. In both LV
failure and BiVAD patients, myocardial samples were obtained at
the time of cardiac transplantation/BiVAD explantation after
cardioplegia infusion, and subsequently flash frozen in liquid
nitrogen for analysis. Trans-esophageal echocardiography was
performed on all patients at the time of surgery. Ventricular
dysfunction and size was graded on a scale of 1–4 (1-normal,
4 abnormal) and interpreted by a pediatric cardiology
echocardiographer. This grading system was used to overcome
the limitations of quantitative echocardiographic measurements of
RV function and to provide a tiered, discrete valuation of
ventricular function solely for the purposes of graphically
illustrating the relationship of myostatin/IGF-1 levels to
myocardial dysfunction. None of the pediatric echocardiographic
readings provide a quantitative measure of RV function, although
LVEF is universally given. However, we thought it was vitally
important for this study to include an analysis of RV function.
Since use of a continuous variable (EF) for the RV was thus not
available, we chose to quantify ventricular function according to
the following system.
LVEF:
Ejection Fraction Grade
.50 1
35–50 2
20–35 3
10–20 4
RVEF:
Echo Description Grade
Normal function 1
Mild dysfunction 2
Mild dysfunction with mild dilation 2.5
Moderate dysfunction with mild dilation 3
Moderate dysfunction with moderate dilation 3.5
Severe dysfunction, severely dilated 4
Western Blot Analysis
Cardiac biopsies obtained for Western blotting were snap-
frozen in liquid nitrogen and prepared as previously described [6].
Briefly, biopsies were weighed and homogenized in 10 uL/ug of
lysis buffer for consistent protein extraction. Next, protein
concentration of the extract was determined, and an equal
amount of protein was loaded per sample (25 ug). Western blot
was then performed for the protein of interest (i.e., myostatin, IGF-
1, MEF-2) as well as for a housekeeping gene (GAPDH) to serve as
a loading control, and data are reported as the ratio of, for
example, myostatin/GAPDH. An internal control sample was also
run on each individual gel to control for gel to gel variation.
Finally, statistical analysis was performed using p,0.05 as a cutoff
for significance using one-way ANOVA with post-hoc Bonferroni
analysis. The following antibodies were used: myostatin (1:500,
Millipore, Temecula, CA), IGF-1 (1:500, R&D Systems, Minne-
apolis, MN), MEF-2 (1:1000, Santa Cruz Biotechnology, Santa
Cruz, CA), and GAPDH (1:4000, Santa Cruz Biotechnology,
Santa Cruz, CA). All Western blots were performed in duplicate to
ensure reproducibility of results.
Statistics
Continuous variables are expressed as mean 6 standard error
(SE) and were compared using independent two-tailed t-testing or
Wilcoxon-Mann-Whitney non-parametric testing, and one-way
ANOVA with post-hoc Bonferroni analysis, when necessary.
Categorical variables were compared by x
2. For all analyses, a p
value of less than 0.05 was considered statistically significant. All
data were analyzed utilizing SPSS 11.5 (SPSS, Chicago, IL).
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Demographics
Demographic data for normal subjects and pediatric patients
from which myocardial tissue samples were obtained are
summarized in Table 1. Normal adult subjects had an average
age of 39.866.2 years, while RVOT patients were much younger
than both OHT and BiVAD patients (8.263.0, 105.9638.4,
89.4627.7 months, respectively). The etiology of disease in
RVOT included Ebstein’s Anomaly, double outlet RV, and
Tetralogy of Fallot; all BiVAD and 3 OHT patients had dilated
cardiomyopathy (DCM). One RVOT patient was maintained on a
single diuretic, in distinct contrast to a much sicker OHT and
BiVAD population which required multiple diuretics, inotropes,
and maximal vasopressors (BiVAD). One BiVAD patient was on
extracorporeal membrane oxygenation prior to BiVAD implan-
tation. Clinical and echocardiographic data are presented in
Table 2. The duration of heart failure was markedly longer in
OHT compared to BiVAD patients (32.3619.9 vs. 11.767.0
months) (p,0.05). Pre-OHT/BiVAD LV function was poor in
both OHT and BiVAD patients (Left ventricular ejection fraction
(%): 2667.5 and 1864.3, respectively), but only BiVAD patients
displayed severe RV dysfunction. RV function in OHT and
RVOT was mildly abnormal. BiVAD patients were supported for
a mean of 4.361.9 days prior to transplantation. All BiVAD
patients were successfully bridged to transplantation.
Myostatin Expression
Myostatin ran at approximately 50 kDa, an apparent molecular
weight that was somewhat higher than predicted, most likely due
to glycosylation (Figure 1A) [12]. Antibody specificity was
confirmed by running samples from a myostatin knock-out mouse
heart and myostatin overexpressing mouse heart along with the
human samples. No significant difference was observed when
Table 1. Myocardial Tissue Study Demographics.
Adult Normal RVOT OHT BiVAD
n5 3 7 3
Age (mos) 39.866.2 8.263.0* 105.9638.4*{ 89.4627.7*{
Weight (kg) 72.3621.1 7.560.6* 31.869.9*{ 27.668.7*{
Male 2 1 3 3
Etiology n/a Ebstein’s Anomaly DCM (3) DCM (3)
DORV Myocarditis
TOF Restrictive CM
HLHS
Hypoplastic TV
Status at
OHT/BiVAD Inotropes n/a 0 6{ 3{
Diuretics n/a 1 6{ 3{
ECMO n/a 0 0 1
PSH n/a Central shunt Norwood/BDG none
BTS
TVR
RVOT-Right Ventricular Outflow Tract, OHT-Orthotopic Heart Transplantation, BiVAD-Biventricular Ventricular Assist Device, DORV-Double Outlet Right Ventricle, TOF-
Tetralogy of Fallot, DCM-Dilated Cardiomyopathy, HLHS-Hypoplastic Left Heart Syndrome, TV-Tricuspid Valve, ECMO-Extracorporeal Membrane Oxygenation, PSH-Past
Surgical History, BDG-Bidirectional Glenn shunt, BTS-Blalock-Taussig Shunt, TVR-Tricuspid Valve Replacement.
*p,0.05 vs. Adult Normal,
{p,0.05 vs. RVOT,
doi:10.1371/journal.pone.0023818.t001
Table 2. Clinical and Echocardiographic Data.
Adult
Normal RVOT OHT BiVAD
Pre-OHT/LVAD n/a n/a 32.3619.9 11.767.0*
Duration of HF (mos)
Pre-OHT/BiVAD LV 6064.0 5361.7 2667.5{ 1864.3*{
Ejection Fraction (%)
Pre-OHT/BiVAD LV 1.060.0 1.060.0 3.060.4{ 4.060.0*{
Dysfunction
a
Pre-OHT/BiVAD RV 1.060.0 1.760.7{ 1.560.2{ 4.060.0*{
Dysfunction
a
Duration of VAD n/a n/a n/a 4.361.9
support (days)
LVEDD (cm) n/a 2.9
b 4.261.0 5.961.5
IVSD (cm) n/a 0.47
b 0.6960.06 0.6360.07
PWT (cm) n/a 0.33
b 0.6760.07 0.6560.15
BiVAD-Biventricular Ventricular Assist Device, HF-Heart Failure, LV-Left
Ventricular, RV-Right Ventricular, OHT-Orthotopic Heart Transplantation,
LVEDD-Left Ventricular End Diastolic Diameter, IVSD-Interventricular Septal
Dimension, PWT-Posterior Wall Thickness.
*p,0.05 vs. OHT,
{p,0.05 vs. Adult Normal, RVOT,
{p,0.05 vs Adult Normal.
aDetails of this grading system can be found in the Methods section.
bTwo RVOT patients–one with DORV and one with TOF–both had very large
muscular VSD’s, and echocardiography was limited in these patients. As a
result, these values represent data from one RVOT patient.
doi:10.1371/journal.pone.0023818.t002
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(Figure 1B). Myostatin expression was increased in LV-OHT vs.
both RV-OHT and RVOT control (Figure 1B) (p,0.05). In
addition, myostatin expression was increased over two-fold in
decompensated HF (BiVAD) vs. both OHT and RVOT control
(Figure 1B) (p,0.05).
Figure 1. Myostatin Expression. A.) Representative Western blot for the myostatin peptide (,50 kDa) in Adult Normal (n=5), pediatric right
ventricular outflow tract (RVOT) (n=3), pediatric orthotopic heart transplant (OHT) (n=7 paired LV and RV), and pediatric biventricular assist device
(BiVAD) myocardial tissue samples (n=3 paired LV and RV). B.) No significant differences were found between Adult Normal and RVOT, while LV-OHT
were significantly higher than RV-OHT samples (p,0.05). BiVAD support increased myostatin more than twice the levels observed in OHT or RVOT in
both LV and RV samples (all p,0.05). (*p,0.05 vs. RVOT, RV-OHT, { p,0.05 vs. LV-OHT).
doi:10.1371/journal.pone.0023818.g001
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A link between myostatin and IGF-1 in the failing heart has
been suggested in the literature [10,11]. The IGF-1 band ran at
approximately 25 kDa, which is the size reported by other
investigators using the same antibody (Figure 2A) [13]. No
significant difference was noted when comparing IGF-1 expression
Figure 2. IGF-1 Expression. A.) Representative Western blot for IGF-1 expression in Adult Normal (n=5), pediatric right ventricular outflow tract
(RVOT) (n=3), pediatric orthotopic heart transplant (OHT) (n=7 paired LV and RV), and pediatric biventricular assist device (BiVAD) myocardial tissue
samples (n=3 paired LV and RV). B.) No significant difference in IGF-1 expression was observed in any cohort.
doi:10.1371/journal.pone.0023818.g002
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Normal (Figure 2B). Next, we calculated the ratio of myostatin to
IGF-1 and plotted this value as a function of ventricular
dysfunction. We found that the myostatin/IGF-1 ratio was
significantly associated with ventricular function: as the myosta-
tion/IGF-1 ratio increased, ventricular function deteriorated
(R
2=0.91, R
2=0.91, respectively) (Figure 3).
MEF-2 Expression
MEF-2 is a transcription factor that has been implicated in the
regulation of myostatin expression [10,11]. MEF-2 ran as a
doublet at approximately 65 kDa (Figure 4A). MEF-2 expression
was significantly higher in LV-OHT compared to Adult Normal
(Figure 4B), and MEF-2 expression was significantly higher in
pediatric BiVAD vs. pediatric OHT, RVOT, and Adult Normal
(Figure 4B). In addition, expression of MEF-2 was upregulated in
myostatin knock-out mice and suppressed in mice overexpressing
myostatin (Figure 4A).
Discussion
To our knowledge, this is the first study investigating myostatin
regulation in the pediatric heart, and our primary findings in this
small cohort of patients are (i) myostatin expression is increased in
compensated LV HF (LV-OHT) compared to paired normal RV
control (RV-OHT) and unpaired normal RV control (RVOT), (ii)
myostatin expression is increased in decompensated biventricular
HF after mechanical unloading (BiVAD) compared to both
compensated HF (OHT) and control (RVOT), (iii) the myosta-
tin/IGF-1 ratio increases in correlation with the degree of
ventricular dysfunction, and (iv) MEF-2 expression is increased
in compensated LV HF (LV-OHT) vs. normal LV (Adult Normal)
and further increased in decompensated biventricular failure after
mechanical unloading (BiVAD).
The role of myostatin in HF has not yet been definitively
determined [14]. Accumulating evidence suggests that myostatin
may be a critical regulator of cardiac remodeling. In animals, it
has been observed that myostatin is upregulated following infarct
in sheep and rats [2,15], volume overload in rats [3], and pressure
overload in mice [4]. In addition, inhibition of myostatin in the
mdx model of DMD accelerates the onset of systolic dysfunction
and LV chamber dilatation [5]. In humans, myostatin has been
reported to be increased in the serum [7], heart [8], and skeletal
muscle [9] of adult HF patients, although one study did report
decreased serum myostatin in HF patients [16]. In addition, we
have previously reported that myostatin activation is increased in
adult HF of both ischemic and non-ischemic etiologies [6], and
now we have determined that myostatin expression is increased in
Figure 3. Myostatin to IGF-1 Ratio. The relationship of myostatin/IGF-1 (left axis) and ventricular dysfunction (right axis) has been plotted for
Adult Normal (n=5), pediatric right ventricular outflow tract (RVOT) (n=3), pediatric orthotopic heart transplant (OHT) (n=7 paired LV and RV), and
pediatric biventricular assist device (BiVAD) myocardial tissue samples (n=3 paired LV and RV). A strong association between increased myostatin/
IGF-1 ratios and worsening ventricular dysfunction exists: Adult Normal samples had low myostatin/IGF-1 levels, while BiVAD samples displayed high
myostatin/IGF-1 levels.
doi:10.1371/journal.pone.0023818.g003
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performed in which myostatin is both inhibited and overexpressed
in an animal model to determine its exact role in HF as well as the
therapeutic potential of manipulation of myostatin expression in
this setting.
It is interesting to note the much larger relative increase in
myostatin after BiVAD support versus LVAD support [6]. The
loss of feedback inhibition after mechanical unloading appears
more pronounced with biventricular failure–whether different
inhibitory pathways are activated/de-activated or other stress
pathways are involved remains under investigation. This increase
in myostatin following mechanical unloading may have been
expected given the fact that exercise training (i.e. loading) results in
decreased skeletal muscle myostatin in healthy humans and in
several pathological states [17], including HF [9] and insulin
resistance [18], as well as in decreased skeletal and cardiac muscle
Figure 4. MEF-2 Expression. A.) Representative Western blot for MEF-2, a transcriptional factor for myostatin, in Adult Normal (n=5), pediatric
right ventricular outflow tract (RVOT) (n=3), pediatric orthotopic heart transplant (OHT) (n=7 paired LV and RV), and pediatric biventricular assist
device (BiVAD) myocardial tissue samples (n=3 paired LV and RV). B.) MEF-2 was significantly increased in LV-OHT compared to Adult Normal control
(#p,0.05). In addition, BiVAD support increased MEF-2 significantly over all patient groups in both RV and LV samples (*p,0.05 vs. Adult Normal,
RVOT, RV-OHT, LV-OHT).
doi:10.1371/journal.pone.0023818.g004
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myostatin may mediate cellular atrophy during periods of
mechanical unloading and that myostatin levels must decrease to
allow physiological hypertrophy during exercise training. Addito-
nal experiments in animal models will need to be performed to test
these hypotheses.
We also examined the relationship between myostatin and IGF-
1 in this study and found that the ratio of myostatin to IGF-1
increased as ventricular function decreased. A link between
myostatin and IGF-1 in the heart has been previously suggested
[10,11]. Shyu et al found that myostatin is increased following
cardiomyocyte stretch in culture and that this increase in
expression is dependent upon IGF-1 secretion and subsequent
signaling through the p38 pathway [11]. Based on these data, a
model has been proposed whereby IGF-1 signals preferentially via
Akt under physiologic conditions to promote physiologic hyper-
trophy and/or cell survival. There is also likely baseline signaling
through p38, which leads to increased myostatin expression via the
MEF-2 transcription factor, thus exerting negative feedback on the
Akt growth pathway via PTEN [11,19,20]. However, under
pathologic conditions such as pressure and/or volume overload in
the failing heart, an unknown trigger may occur, which causes
IGF-1 to signal predominantly through the p38/MEF-2 pathway
and which results in increased expression of myostatin out of
proportion to IGF-1. The stimulus for this trigger may be
pathologic stretch in HF, as suggested by Shyu et al [11]. If this is
the case, we believe that an increased myostatin to IGF-1 ratio
may be a clinical marker of worsening HF. Indeed, we observed
increased MEF-2 in conditions where we also observed increased
myostatin, which supports the proposed pathway. Future effort
will be directed towards examining p38 and Akt signaling in these
patients.
It is unclear at this point whether the increased myostatin to
IGF-1 ratio causes or contributes to ventricular dysfunction in HF.
It is known that decreased activity of the growth hormone (GH)/
IGF-1 axis (low IGF-1 syndrome) is predictive of poorer outcomes
and higher mortality in HF [21], and that GH replacement, which
increases IGF-1 expression, can lead to increased peak oxygen
uptake and exercise duration as well as higher quality of life [22].
This therapy may function by restoring the physiological
myostatin/IGF-1 ratio and overcoming pathologic repression of
IGF-1 by myostatin. Our findings represent a small sample cohort,
and additional experiments in which expression of both myostatin
and IGF-1 is manipulated will need to be performed in an animal
model of HF to delineate the significance of the myostatin/IGF-1
ratio in HF further.
In summary, we have demonstrated for the first time that
myostatin expression is increased in pediatric compensated LV
failure and further increases in decompensated biventricular
failure after mechanical support. In addition, we observed that
the myostatin/IGF-1 ratio may increase as ventricular function
decreases. Future investigation is needed to determine the effects
of myostatin inhibition and overexpression in HF.
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